Literature DB >> 36267220

Cephalomedullary nailing for reverse oblique intertrochanteric fractures 31A3 (AO/OTA).

Emanuela Marsillo1, Andrea Pintore1, Giovanni Asparago1, Francesco Oliva1, Nicola Maffulli2.   

Abstract

Introduction: Reverse oblique intertrochanteric fractures are classified by the Orthopaedic Trauma Association [OTA]/[AO] as 31A3, and account for up to one-third of all hip fractures, and 2-23% of all trochanteric fractures. The treatment of choice of those fractures is intramedullary nailing as it decreases soft tissue damage and permits early weight bearing. Material and methods: A retrospective comparative study was conducted on patients surgically treated for 31A3 fractures from October 2018 to January 2022 in a high-volume regional referral centre. All the patients had been treated with intramedullary nailing.
Results: The selected group included 11 males (16%) and 59 females (84%), with a mean age of 83.6 years (range 61 to 96 years). A Trigen Intertan Nail was the most frequent choice of intramedullary nailing in 33 patients (47%), an Elos Long nail was chosen in 19 cases (27%), while a ZNN nail was used in 18 patients (26%). The mean time between admission and surgery was 2.5 days, with a mean Hb value of 10.5 g/dl reported preoperatively.
Conclusion: Patients treated with an Intertan nail reported the lowest TAD, CALTAD, and TALCALTAD mean radiographic values, and the lowest rate of Hb loss and blood transfusions.

Entities:  

Keywords:  31A3.; femur; fractures; nail; reverse oblique intertrochanteric; surgery

Year:  2022        PMID: 36267220      PMCID: PMC9568432          DOI: 10.52965/001c.38560

Source DB:  PubMed          Journal:  Orthop Rev (Pavia)        ISSN: 2035-8164


  37 in total

1.  Cross-match protocols for femoral neck fractures--finding one that can work.

Authors:  A M Khan; N Mushtaq; K Giannakas; D H Sochart; J G Andrews
Journal:  Ann R Coll Surg Engl       Date:  2004-01       Impact factor: 1.891

2.  Failure of femoral head fixation: a cadaveric analysis of lag screw cut-out with the gamma locking nail and AO dynamic hip screw.

Authors:  R C Haynes; R G Pöll; A W Miles; R B Weston
Journal:  Injury       Date:  1997 Jun-Jul       Impact factor: 2.586

3.  Management of hip fracture in adults: summary of NICE guidance.

Authors:  Saoussen Ftouh; Antonia Morga; Cameron Swift
Journal:  BMJ       Date:  2011-06-21

4.  Subtrochanteric fractures of the femur. Results of treatment with the 95 degrees condylar blade-plate.

Authors:  C Kinast; B R Bolhofner; J W Mast; R Ganz
Journal:  Clin Orthop Relat Res       Date:  1989-01       Impact factor: 4.176

Review 5.  Unstable pertrochanteric femoral fractures.

Authors:  Philip J Kregor; William T Obremskey; Hans J Kreder; Marc F Swiontkowski
Journal:  J Orthop Trauma       Date:  2014-08       Impact factor: 2.512

6.  Nail or plate fixation of intertrochanteric hip fractures: changing pattern of practice. A review of the American Board of Orthopaedic Surgery Database.

Authors:  Jeffrey O Anglen; James N Weinstein
Journal:  J Bone Joint Surg Am       Date:  2008-04       Impact factor: 5.284

7.  Predictors of failure for cephalomedullary nailing of proximal femoral fractures.

Authors:  A Kashigar; A Vincent; M J Gunton; D Backstein; O Safir; P R T Kuzyk
Journal:  Bone Joint J       Date:  2014-08       Impact factor: 5.082

Review 8.  Burden of major musculoskeletal conditions.

Authors:  Anthony D Woolf; Bruce Pfleger
Journal:  Bull World Health Organ       Date:  2003-11-14       Impact factor: 9.408

Review 9.  Management of Subtrochanteric Proximal Femur Fractures: A Review of Recent Literature.

Authors:  Christopher Jackson; Mina Tanios; Nabil Ebraheim
Journal:  Adv Orthop       Date:  2018-10-28

10.  Impact of timing of surgery in elderly hip fracture patients: a systematic review and meta-analysis.

Authors:  Thomas Klestil; Christoph Röder; Christoph Stotter; Birgit Winkler; Stefan Nehrer; Martin Lutz; Irma Klerings; Gernot Wagner; Gerald Gartlehner; Barbara Nussbaumer-Streit
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.